From 5da6396174cc70c654f4966c87c03a1e0817d3a5 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Thu, 21 Mar 2024 14:20:59 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Posts.md | 30 +++--------------------------- 1 file changed, 3 insertions(+), 27 deletions(-) diff --git a/pages/STOP2030___Web___Posts.md b/pages/STOP2030___Web___Posts.md index ba0718d9..b02e567d 100644 --- a/pages/STOP2030___Web___Posts.md +++ b/pages/STOP2030___Web___Posts.md @@ -23,31 +23,7 @@ The general goals of the REALISE study are to validate the benefits of the FDC through this pragmatic trial within the context of a mass drug administration (MDA) program, to evaluate safety as a primary endpoint, and effectiveness profile as a secondary endpoint, in a large population of school-aged children. - The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and - 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, - serving as an active control group, will receive a single dose of albendazole - 400mg, the current standard. + The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, serving as an active control group, will receive a single dose of albendazole 400mg, the current standard. - - - If you want to review the full - protocol, please visit the REALISE study's page on [clinicaltrials.gov](https://urldefense.com/v3/__http:/clinicaltrials.gov/__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncV4ibvmQ$) or PACTR (trial id: - PACTR202402529220760). - #+END_VERSE At STOP2030, we aim to provide a pharmacological tool that aids in achieving the WHO's goals for soil-transmitted helminthiasis (STH) by 2030. That's why we are thrilled to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial yet, has been registered on clinicaltrials.gov and the Pan African Clinical Trial Registry (id number PACTR202402529220760). - - This randomized control trial is a Cohort Event Monitoring study designed to evaluate the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazole and ivermectin in large - populations, compared to the standard dose of albendazole currently used against STH. We plan to recruit around 20,000 school-aged children between 5 and 17 years old in Kenya and Ghana, starting the the second semester of 2024. - - The general goals of the REALISE study are to validate the benefits of the FDC through this pragmatic trial within the context of a mass drug administration (MDA) program, to evaluate safety as a primary endpoint, and effectiveness profile as a secondary endpoint, in a large population of school-aged children. - The clinical trial will have two - arms, randomized by school. One arm will receive a single dose of the - fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and - 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, - serving as an active control group, will receive a single dose of albendazole - 400mg, the current standard. - - - - If you want to review the full - protocol, please visit the REALISE study's page on [clinicaltrials.gov](https://urldefense.com/v3/__http:/clinicaltrials.gov/__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncV4ibvmQ$) or PACTR (trial id: - PACTR202402529220760). \ No newline at end of file + If you want to review the full protocol, please visit the REALISE study's page on clinicaltrials.gov or PACTR (trial id: PACTR202402529220760). + #+END_VERSE \ No newline at end of file